IQVIA Holdings Inc. $IQV Stock Holdings Boosted by Adage Capital Partners GP L.L.C.

Key Points

• Adage Capital Partners GP L.L.C. increased its stake in IQVIA Holdings Inc. by 85.8%, acquiring an additional 33,341 shares worth approximately $12.7 million.
• IQVIA reported earnings of $2.81 per share for the last quarter, exceeding analyst expectations, and revenue grew by 5.3% year-over-year.
• Analysts maintain a generally favorable outlook on IQVIA, with an average target price of $229.86 reflecting a "Moderate Buy" sentiment.

Adage Capital Partners GP L.L.C. increased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 85.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 72,201 shares of the medical research company's stock after purchasing an additional 33,341 shares during the period. Adage Capital Partners GP L.L.C.'s holdings in IQVIA were worth $12,729,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Continuum Advisory LLC increased its position in IQVIA by 3.7% during the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after purchasing an additional 64 shares during the last quarter. Ballentine Partners LLC grew its position in IQVIA by 4.9% during the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after acquiring an additional 69 shares during the period. Independent Advisor Alliance increased its stake in IQVIA by 4.2% during the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock worth $318,000 after acquiring an additional 72 shares during the last quarter. ST Germain D J Co. Inc. lifted its stake in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. Finally, Nemes Rush Group LLC grew its holdings in shares of IQVIA by 15.0% during the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after purchasing an additional 81 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

IQVIA Stock Up 1.2%

Shares of IQV traded up $2.21 during trading on Tuesday, reaching $189.89. The company's stock had a trading volume of 1,200,874 shares, compared to its average volume of 1,160,792. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $248.03. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a market cap of $32.28 billion, a price-to-earnings ratio of 27.48, a P/E/G ratio of 2.06 and a beta of 1.32. The company has a fifty day moving average of $181.03 and a two-hundred day moving average of $167.36.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on IQV shares. Redburn Partners set a $214.00 price target on shares of IQVIA in a report on Wednesday, September 3rd. Barclays upped their price target on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research report on Wednesday, July 23rd. William Blair reissued an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Truist Financial upped their target price on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Finally, Mizuho raised their target price on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Eighteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $229.64.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.